http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022151532-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09cd0fb999f2f3d3abe1b581a5bb1a88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00e39b7a0aa69226ff694dbe4416cbdd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7fda2d74d440f3b7e886b640883b169e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 |
| filingDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc8b671140f4b26589f3fb185a2692ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7132d411cab6aebf60cc69333917808b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_474575917c6ac6bc8a9b1983969ff3ed |
| publicationDate | 2022-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022151532-A1 |
| titleOfInvention | Application of tegaserod maleate in treatment of acute myelocytic leukemia and colorectal cancer |
| abstract | The present invention relates to the field of molecular biology, and in particular to tumor treatment. Specifically, tegaserod maleate obtained by screening from drugs disclosed in the prior art has an effect of treating acute myelocytic leukemia and colorectal cancer; cytological experiments and animal experiments prove that tegaserod maleate can inhibit the proliferation of acute myelocytic leukemia cell lines and human colorectal cancer cell lines, induce apoptosis and block a cell cycle in a G1 phase; in a mouse model, the survival time of a mouse can be significantly prolonged and the progression of leukemia can be blocked; moreover, it is also found for the first time that by inhibiting the function of m6A recognition protein YTHDF1 in a tumor cell, i.e., blocking the binding of YTHDF1 to an RNA containing an m6A modification, tegaserod maleate can inhibit a translation capability of a downstream key target gene to achieve the described effect. |
| priorityDate | 2021-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.